Cited by 109Obstructive Sleep Apnea ResearchSleep and related disordersSleep and Work-Related Fatigue

Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea

Schwartz, Jonathan R.L., Hirshkowitz, Max, Erman, Milton K., Schmidt-Nowara, Wolfgang·2003·Chest

Abstract

Study objectives The purpose of this 12-week study was to evaluate the efficacy and safety of adjunct modafinil to treat excessive sleepiness in patients with obstructive sleep apnea (OSA) who experience residual sleepiness despite regular nasal continuous positive airway pressure (nCPAP) use. Design Twelve-week, open-label trial. Setting Twenty-two centers in the United States. Patients We studied 125 patients with moderate-to-severe OSA (ie, respiratory disturbance index > or =15) before nCPAP therapy and residual daytime sleepiness (Epworth sleepiness scale [ESS] score > or =10) despite effective and regular nCPAP therapy. Patients were studied after completing a 4-week, double-blind, placebo-controlled trial of nCPAP plus modafinil for the treatment of residual daytime sleepiness. Interventions and measurements Patients received individually titrated doses of modafinil (200 to 400 mg qd). Sleepiness was assessed using the ESS, quality of life was evaluated using the Functional Outcomes of Sleep Questionnaire (FOSQ), and the overall clinical effect was indexed using the clinical global impression of change scale. Adverse events, nCPAP use, and vital sign measurements were also recorded. Results The significant improvements in daytime wakefulness and sleep-related functional status observed with modafinil treatment during the 4-week, double-blind study were maintained throughout 12 weeks of open-label treatment: week 12 ESS, 7.8 (4.7) vs 14.4 (3.1) at double-blind baseline; week 12 FOSQ, 3.3 (0.6) vs 14.4 (2.7) at double-blind baseline (mean [SD]). The percentage of patients rated as clinically improved increased from 83% after 1 week to > or =93% after 2 to 12 weeks of open-label treatment. Mean (SD) nCPAP use decreased from 6.3 (1.3) h/night at baseline to 5.9 (1.4) h/night (p = 0.004) during open-label treatment. The most common adverse events were headache (28%), anxiety (16%), and nervousness (14%). Conclusions Modafinil remained effective and well tolerated as an adjunct therapy for residual daytime sleepiness even after 12 weeks of daily dosing in patients with OSA receiving nCPAP therapy.

Integrity signals

Registry

Crossref · 10.1378/chest.124.6.2192

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Schwartz, J. R. L., Hirshkowitz, M., Erman, M. K., & Schmidt-Nowara, W.
Affiliations
  • INTEGRIS Baptist Medical Center (US)
  • Veterans Health Administration (US)
Corresponding author
Schwartz, Jonathan R.L.
Venue
Chest
Publisher
Elsevier BV
Published
2003-12
Volume
124
Issue
6
Pages
2192-2199
ISSN
0012-3692 (ISSN-L)
OpenAlex
W2163375570
Cited by
107
References
39
Citations by year
2024: 3 · 2023: 4 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 3 · 2013: 5 · 2012: 7
FWCI
2.88
Type
journal article
Language
en
Open access
closed
Locations
  • CHEST Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
Keywords
modafinil, obstructive sleep apnea, daytime sleepiness, residual daytime sleepiness, adjunctive therapy, continuous positive airway pressure, Epworth Sleepiness Scale, quality of life, adverse events, long-term efficacy, wakefulness-promoting agents, headache, anxiety, Functional Outcomes of Sleep Questionnaire, clinical global impression
MeSH terms
Modafinil, Adult, Aged, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Chemotherapy, Adjuvant, Sleep Disorders, Circadian Rhythm, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review